Evidence map›Paper›PMID 41282811›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.

Marcilio J Fumagalli, Anna Kaczynska, Marius Allombert, Ágata Lopes-Ribeiro, Mariângela de Oliveira Silva, Brianna J Hernandez, Christy Lavine, Sebastian M Espinosa, Helen Brown, Hanna Box and 25 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Marcilio J FumagalliLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0002-0207-5423
Anna KaczynskaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.
Marius AllombertLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0009-0007-9098-0418
Ágata Lopes-RibeiroLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0002-1705-5388
Mariângela de Oliveira SilvaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0002-0975-7187
Brianna J HernandezLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.
Christy LavineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6135-0547
Sebastian M EspinosaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Helen BrownNuffield Department of Medicine, University of Oxford, Oxford, UK and the Oxford NIHR Biomedical Research Centre, Oxford, UK.ORCID 0009-0008-2688-1471
Hanna BoxSchool of Public Health, Imperial Clinical Trials Unit, Imperial College London, London, UK.
Emanuela FalaschettiSchool of Public Health, Imperial Clinical Trials Unit, Imperial College London, London, UK.
Louise-Rae CherrillSchool of Public Health, Imperial Clinical Trials Unit, Imperial College London, London, UK.
Tamara ElliottDepartment of Infectious Disease, Imperial College London, London, UK.
Ming LeeDepartment of Infectious Disease, Imperial College London, London, UK.
Julie FoxGuy's and St Thomas Hospital NHS Foundation Trust, London, UK.
Sarah PettUniversity College London, London, UK.
Amanda ClarkeUniversity Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Alison UrielManchester University NHS Foundation Trust, Manchester, UK.
Ole SogaardDepartment of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-9107-2023
Rebecca SutherlandWestern General Hospital, NHS Lothian Trust, Edinburgh, UK.
Marta BoffitoChelsea and Westminster Hospital, London, UK.
Sabine Kinloch-LoesUniversity College London, London, UK.
Chloe OrkinQueen Mary University of London, London, UK.
Simon CollinsHIV i-Base, London, UK.
Panagiota ZacharopoulouNuffield Department of Medicine, University of Oxford, Oxford, UK and the Oxford NIHR Biomedical Research Centre, Oxford, UK.ORCID 0000-0002-3645-662X
Nicola RobisonNuffield Department of Medicine, University of Oxford, Oxford, UK and the Oxford NIHR Biomedical Research Centre, Oxford, UK.
Cintia BittarLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0002-2048-4589
Thiago OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0002-2654-0879
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0002-5976-9717
Mila JankovicLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0001-9696-5234
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6444-3562
John FraterNuffield Department of Medicine, University of Oxford, Oxford, UK and the Oxford NIHR Biomedical Research Centre, Oxford, UK.ORCID 0000-0001-7163-7277
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0003-1727-8693
Sarah FidlerNIHR Imperial Biomedical Research Centre, Imperial College London, London, UK.ORCID 0000-0003-1676-7583
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY USA.ORCID 0000-0003-0592-8564

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2012 to 2018
$131.5M
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vinayaka R. Prasad · 2017 to 2026
$28.3M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2M
Gates Foundation INV-002705Gates Foundation INV-008540Gates Foundation INV-036842NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI129795NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164565
6 · The paper itself

Abstract

RIO is an ongoing double blind randomized placebo controlled human trial in which participants that started antiretroviral therapy (ART) during primary or early-stage infection underwent treatment interruption and were randomly assigned to a group receiving one or two doses of two long acting broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS (Arm A), or saline (Arm B). The two arms differed significantly in time to viral rebound, ART restart and number of individuals that remained off therapy after 96 weeks (p=0.001)

Identifiers

PMID41282811
PMCPMC12637763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.